Ellis Jennifer M, Reddy Prabashni
School of Pharmacy, University of Connecticut, Storrs, USA.
Ann Pharmacother. 2002 Mar;36(3):375-9. doi: 10.1345/aph.1A245.
To assess the time-dependent effects of Panax ginseng on health-related quality of life (HRQOL) by use of a general health status questionnaire.
Subjects were randomized in a double-blind manner to P. ginseng 200 mg/d (n = 15) or placebo (n = 15) for 8 weeks. The Short Form-36 Health Survey version 2 (SF-36v2), a validated general health status questionnaire, was used to assess HRQOL at baseline and at 4 and 8 weeks. HRQOL between the groups was compared by use of repeated-measures analysis of covariance. A p value <0.05 was considered statistically significant.
There were no significant differences in baseline demographics and SF-36v2 scores between the groups. After 4 weeks of therapy, higher scores in social functioning (P. ginseng 54.9+/-4.6 vs. placebo 49.2+/-6.5; p = 0.014), mental health (P. ginseng 52.2+/-7.7 vs. placebo 47.2+/-7.3; p = 0.075), and the mental component summary (P. ginseng 51.3+/-7.4 vs. placebo 44.3+/-8.3; p = 0.019) scales were observed in patients randomized to P. ginseng; these differences did not persist to the 8-week time point. The incidence of adverse effects was 33% in the P. ginseng group compared with 17% in the placebo group (p = 0.40). Subjects given P. ginseng (58%) were more likely to state that they received active therapy than subjects given placebo (17%; p < 0.05).
P. ginseng improves aspects of mental health and social functioning after 4 weeks of therapy, although these differences attenuate with continued use.
通过使用一般健康状况问卷评估人参对健康相关生活质量（HRQOL）的时间依赖性影响。
将受试者以双盲方式随机分为人参组（200毫克/天，n = 15）或安慰剂组（n = 15），为期8周。使用经过验证的一般健康状况问卷简明健康调查简表第2版（SF - 36v2）在基线、4周和8周时评估HRQOL。采用重复测量协方差分析比较两组之间的HRQOL。p值<0.05被认为具有统计学意义。
两组之间的基线人口统计学和SF - 36v2评分无显著差异。治疗4周后，随机分组至人参组的患者在社会功能（人参组54.9±4.6 vs. 安慰剂组49.2±6.5；p = 0.014）、心理健康（人参组52.2±7.7 vs. 安慰剂组47.2±7.3；p = 0.075）和心理成分总结（人参组51.3±7.4 vs. 安慰剂组44.3±8.3；p = 0.019）量表上得分更高；这些差异在8周时间点未持续存在。人参组的不良反应发生率为33%，而安慰剂组为17%（p = 0.40）。服用人参的受试者（58%）比服用安慰剂的受试者（17%）更有可能表示他们接受了积极治疗（p < 0.05）。
人参在治疗4周后可改善心理健康和社会功能方面，尽管随着持续使用这些差异会减弱。
